Functional interference between retinoic acid or steroid hormone receptors and the oncoprotein Fli-1

Oncogene
T G DarbyRenate J Scheibe

Abstract

The Fli-1 protein is a member of the ets proto-oncogene family, whose overexpression is a consequence of Friend murine leukemia virus (F-MuLV) integration in Friend erythroleukemic cells. We present evidence that Fli-1 and the retinoic acid receptor (RAR alpha) can reciprocally repress one another's transcriptional activation. Overexpression of Fli-1 inhibits the retinoic acid-induced activation of genes carrying a functional retinoic acid response element (RARE). Conversely, RAR alpha is able to repress Fli-1-mediated transcriptional activation. Transfection analysis of RAR alpha and Fli-1 mutants in cultured cells demonstrate that the DNA binding domain of RAR alpha and the N-terminal region of Fli-1 are required for repression. Gel retardation analysis demonstrates that RAR alpha cannot bind to the Fli-1 binding site in the E74 promoter and the expression of Fli-1 does not affect RAR alpha binding to DNA. Furthermore, the data suggest an indirect interaction between Fli-1 and RAR alpha mediated by a 'bridging' factor(s) present in nuclear extracts from RM10 erythroleukemia cells. Fli-1 also interferes with the action of receptors for thyroid or glucocorticoid hormone in several hematopoietic cell lines. The RA-induced differ...Continue Reading

Citations

Feb 1, 2003·Gene·Tsuneyuki Oikawa, Toshiyuki Yamada
Feb 26, 2000·European Journal of Biochemistry·L C TsaiT C Chang
Jul 23, 1999·Current Opinion in Oncology·H KovarA Zoubek
Jan 31, 2003·Molecular and Cellular Biology·Joëlle StarckFrançois Morle
Oct 19, 2005·Proceedings of the National Academy of Sciences of the United States of America·GuoQiang SunAlexander S Raikhel
Dec 4, 2003·Médecine sciences : M/S·Virginie Vlaeminck-GuillemMartine Duterque-Coquillaud
Aug 12, 2008·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Sarah BradshawXian K Zhang
Nov 18, 2006·Journal of Cellular Physiology·Joachim D MeissnerRenate J Scheibe
Feb 15, 2001·Oncogene·V I Sementchenko, D K Watson
Nov 17, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lukasz StawskiMaria Trojanowska
Oct 19, 2001·Oncogene·A Arvand, C T Denny
Feb 15, 2001·Oncogene·A H Truong, Y Ben-David
Nov 7, 2003·Oncogene·Virginie Vlaeminck-GuillemMartine Duterque-Coquillaud
Jan 15, 2004·The Journal of Biological Chemistry·Sachiko MatsudaDavid M Heery
Jul 27, 2004·Oncogene·Ramugounder RamakrishnanE Shyam P Reddy
Sep 22, 1999·Molecular and Cellular Biology·R FenrickS W Hiebert
Sep 9, 2005·The Journal of Biological Chemistry·Emile van den AkkerJacques Ghysdael
Oct 7, 2004·The Journal of Biological Chemistry·Pascale JackersDennis K Watson

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.